Talk:CCL17

January 2021 - March 2021
This article was the subject of a Wiki Education Foundation-supported course assignment, between 4 January 2021 and 15 March 2021. Further details are available on the course page. Student editor(s): Immcarle147.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 09:37, 18 January 2022 (UTC)

I am going to add the following sources:

1.	Korbecki, J. et al. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4. IJMS 21, 8412 (2020).

2.	Furue, M. T helper type 2 signatures in atopic dermatitis. J Cutan Immunol Allergy 1, 93–99 (2018).

3.	Ohue, Y. & Nishikawa, H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci 110, 2080–2089 (2019).

--Immcarle147 (talk) 17:00, 29 January 2021 (UTC)

Questions
Are there any major functions of CCL17 other than T cell recruitment through CCR4 receptors? That section seems important.--Immcarle168 (talk) 02:48, 18 January 2022 (UTC)

Additions
I reworked the "Allergies" section into a broader "Autoimmune" section where I discuss the ways that CCL17 affects several autoimmune disorders. Mostly I found information about atopic dermatitis (eczema) and some on multiple sclerosis, and then I listed several others that high levels of CCL17 is reported to correlate with.Immcarle168 (talk) 04:56, 10 March 2022 (UTC)